GRI logo

GRI Bio NasdaqCM:GRI Stock Report

Last Price

US$0.48

Market Cap

US$4.4m

7D

-24.2%

1Y

-97.3%

Updated

07 Feb, 2025

Data

Company Financials +

GRI Stock Overview

A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. More details

GRI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

GRI Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for GRI Bio
Historical stock prices
Current Share PriceUS$0.48
52 Week HighUS$21.06
52 Week LowUS$0.30
Beta0
1 Month Change-34.79%
3 Month Change-45.27%
1 Year Change-97.25%
3 Year Changen/a
5 Year Changen/a
Change since IPO-99.94%

Recent News & Updates

Recent updates

Shareholder Returns

GRIUS BiotechsUS Market
7D-24.2%-1.1%-0.3%
1Y-97.3%-2.3%20.4%

Return vs Industry: GRI underperformed the US Biotechs industry which returned 0.9% over the past year.

Return vs Market: GRI underperformed the US Market which returned 22% over the past year.

Price Volatility

Is GRI's price volatile compared to industry and market?
GRI volatility
GRI Average Weekly Movement14.7%
Biotechs Industry Average Movement11.3%
Market Average Movement6.0%
10% most volatile stocks in US Market18.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: GRI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: GRI's weekly volatility has decreased from 26% to 15% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20094W. Hertzwww.gribio.com

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development.

GRI Bio, Inc. Fundamentals Summary

How do GRI Bio's earnings and revenue compare to its market cap?
GRI fundamental statistics
Market capUS$4.43m
Earnings (TTM)-US$8.26m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$8.26m
Earnings-US$8.26m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.92
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GRI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 02:46
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GRI Bio, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Matthew KellerH.C. Wainwright & Co.